ストックスクリーナーアプリを入手
26.79
0.04%
-0.01
アフターアワーズ：
26.78
-0.010
-0.04%
前日終値:
$26.80
開ける：
$26.66
24時間の取引高:
23.15M
Relative Volume:
0.57
時価総額：
$152.69B
収益：
$63.32B
当期純損益:
$7.52B
株価収益率:
20.54
EPS:
1.3043
ネットキャッシュフロー:
$9.48B
1週間 パフォーマンス:
+0.11%
1か月 パフォーマンス:
+10.47%
6か月 パフォーマンス:
-2.86%
1年 パフォーマンス:
+6.69%
1日の値動き範囲:
$26.42
$26.91
1週間の範囲:
$26.18
$27.20
52週間の値動き範囲:
$23.58
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.79 | 149.96B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,180.16 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.35 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.46 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.84 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.88 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
PFE price outlook: Pfizer pressing against 0.618 arc. Potential breakout toward $27.95 - FXStreet
Pfizer Stock And 2 AI Healthcare Picks Built Around Productivity Growth - simplywall.st
Patriot Financial Group Insurance Agency LLC Sells 90,653 Shares of Pfizer Inc. $PFE - marketbeat.com
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $30.31 Million Stake in Pfizer Inc. $PFE - marketbeat.com
PFE Stock Quote Price and Forecast - CNN
Pfizer’s CEO Just Bought $1 Million of Stock at $26. Here’s Where the Stock Could Go - TIKR.com
Pfizer Inc. $PFE Stock Position Lifted by Park National Corp OH - marketbeat.com
Pfizer Inc. $PFE Holdings Lifted by QSM Asset Management Ltd - marketbeat.com
Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE - marketbeat.com
Pfizer Inc. • Robinhood Token Price, PFE Price, Live Charts, and Marketcap - Coinbase
Pfizer Inc. • Robinhood Token (PFE) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
Dividend HistoryPfizer (PFE) - Zacks Investment Research
New owner secures mystery tenant for Everett plant shelved by Pfizer - The Business Journals
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp - Investing.com
Pfizer Veteran's Khartis Therapeutics Launches With $95 Million for Oral Thyroid Eye Disease Drug - finance.biggo.com
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase - Barron's
Breakthrough Properties Buys Biomanufacturing Campus in Everett, Secures Lease - MyNorthwest.com
Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market - TipRanks
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Benzinga
What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders - simplywall.st
EMA Accepts Pfizer/Valneva’s Lyme Disease Vaccine Filing In Global First - insights.citeline.com
Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock - Benzinga
EMA Begins Review of Pfizer-Valneva Lyme Disease Vaccine - Contract Pharma
QRG Capital Management Inc. Acquires 49,804 Shares of Pfizer Inc. $PFE - marketbeat.com
EMA validates Pfizer-Valneva Lyme disease vaccine application By Investing.com - Investing.com Canada
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - The Manila Times
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money - Fast Company
Pfizer (NYSE:PFE) Trading 1.9% HigherWhat's Next? - marketbeat.com
Pfizer (PFE) reports $170.4M across 20 institutional holdings in 13F - Stock Titan
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Pfizer Inc. (NYSE:PFE) Keeps Drawing Healthcare Focus? - Kalkine Media
Enterprise AI Profile: Pfizer's Federated AI Pipeline - Futuriom
Could Pfizer (NYSE:PFE) Draws Notice Amid Post-Pandemic Portfolio Shift Stay in Focus? - Kalkine Media
Why Is Pfizer (NYSE:PFE) Draws Dividend Focus as Inflation Data Calms Markets Worth Watching? - Kalkine Media
How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story - Yahoo Finance
Pfizer CEO Bourla Buys $1 Million in Shares as Drugmaker Fights Growth Doubts - finance.biggo.com
Pfizer stock steadies after Q2 2026 beat and modest guidance lift - AD HOC NEWS
Pfizer (NYSE:PFE) Guidance & Pipeline Put Valuation In Focus - kalkinemedia.com
Pfizer CEO Buys $1 Million of Stock - TradingView
Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance - simplywall.st
Pfizer, Inc. Stock 12‑Month Price Target Cut to $28.28, Implies 7% Upside - TradingView
China Surpasses US in Drug Trials as Washington RespondsPfizer (NYSE:PFE), Merck & Co (NYSE:MRK) - Benzinga
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call - Yahoo Finance
Pfizer CEO Albert Bourla Acquires 38,000 Shares in August 2026 Open-Market Purchase - Kalkine Media
Pfizer (NYSE:PFE) Draws Value-Focused Attention As Pharma Steadies Amid Caution - Kalkine Media
Pfizer (NYSE:PFE) Shares Down 1.2%Time to Sell? - MarketBeat
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pfizer Insider Bought Shares Worth $1,000,920, According to a Recent SEC Filing - marketscreener.com
Insulet hires Pfizer alum Joan Campion to lead external comms - Medical Marketing and Media
Listening to the Hemophilia Community: Pfizer Survey Reveals Unspoken Compromises - Pfizer
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
1.78%
大文字化:
|
ボリューム (24 時間):